Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
September has been designated as National Sickle Cell Awareness Month for the continued fostering of education surrounding sickle cell disease management.
[[thumbnail_alt_text]]
Researchers at the Rensselaer Polytechnic Institute recently published a study on the use of the FDA-approved anticoagulant heparin in patients with COVID-19.
[[thumbnail_alt_text]]
Azacitidine showed an overall survival benefit among patients with acute myeloid leukemia compared with a placebo. 
[[thumbnail_alt_text]]
Current advances in the analysis of the mutational status of different genes are providing investigators insights into new treatment pathways that can improve outcomes for patients. 
[[thumbnail_alt_text]]
A new medication for certain rare blood cancers has now become available through a limited distribution with AllianceRx Walgreens Prime.
[[thumbnail_alt_text]]
Targeted combination therapy found to improve overall survival with rapid and durable treatment responses in patients with acute myeloid leukemia.
[[thumbnail_alt_text]]
CAR T-cell therapy involves collecting a patient’s blood, extracting the T cells within the blood, and returning the remaining blood back into the body, a process called leukapheresis.
[[thumbnail_alt_text]]
The FDA has issued an emergency use authorization for the use of convalescent plasma in the treatment of COVID-19. 
[[thumbnail_alt_text]]
The FDA has approved an expansion of the prescribing information for carfilzomib to include its use with daratumumab and dexamethasone for the treatment of relapsed or refractory multiple myeloma.
[[thumbnail_alt_text]]
Panel discusses the importance of patient education regarding toxicities as well as different treatment regimens for chronic lymphocytic leukemia.
 
[[thumbnail_alt_text]]
Belantamab mafodotin-blmf is the first anti-BCMA therapy approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.
[[thumbnail_alt_text]]
As the most accessible member of the health care team, the pharmacist can provide patients with cancer with the information and support necessary to get through what might be the most challenging time of their lives.